Author:
Dalenc F.,Bergé Y.,Roché H.
Reference88 articles.
1. Klijn JG, Berns PM, Schmitz PI et al. (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 13: 3–17
2. Rimawi M, Shetty PB, Weiss HL et al. (2010) Epidermal growth factor receptor expression in breast cancer association with biological phenotype and clinical outcomes. Cancer 116: 1234–1242
3. Nielsen TO, Hsu FD, Jensen K et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367–5374
4. Diaz LK, Cryns VL, Symmans F et al. (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical experince. Adv Anat Pathol 14: 419–430
5. Giltane JM, Rydén L, Cregger M et al. (2007) Quantitative measurement of epidermal growth factor is a negative predictive factor for tamoxifen response in hormonepositive premenopausal breast cancer. J Clin Oncol 25: 3007–3014